Lv5
920 积分 2024-05-01 加入
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
6个月前
已完结
EHBP1 suppresses liver fibrosis in metabolic dysfunction-associated steatohepatitis
7个月前
已完结
Resistance to Immunotherapy in Non-small Cell Lung Cancer: Unraveling Causes, Developing Effective Strategies, and Exploring Potential Breakthroughs
7个月前
已完结
Hallmarks of Cancer: New Dimensions
8个月前
已完结
Catumaxomab: First Approval
8个月前
已关闭